News Releases
Aug 1, 2022
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma Read more
Jun 29, 2022
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia Read more
Jun 3, 2022
ALX Oncology Announces Evorpacept Clinical Program Updates Read more
Jun 1, 2022
ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference Read more
May 9, 2022
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more
Apr 12, 2022
ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors Read more
Mar 2, 2022
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer Read more
Feb 28, 2022
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Read more
Jan 27, 2022
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer Read more
Jan 10, 2022
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 Read more